Establishment of a syngeneic orthotopic model of prostate cancer in immunocompetent rats

Suzuki, Shugo; Naiki‐Ito, Aya; Kuno, Toshiki; Punfa, Wanisa; Long, Ne; Kato, Hiroyuki; Inaguma, Shingo; Komiya, Masami; Shirai, Tomoyuki; Takahashi, Satoru

doi:10.1293/tox.2014-0050

Cited by 4 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An androgen‐independent human prostate cancer cell line (PC3) was purchased from ATCC. The androgen‐independent, androgen receptor‐negative rat prostate cancer cell line (PLS10) was established in our laboratory . PC3 and PLS10 cells were cultured in RPMI‐1640 with 10% FBS, 5 mmol/L l ‐glutamine, 50 IU/mL penicillin and 50 mg/mL streptomycin and maintained in a humidified incubator with an atmosphere comprising 95% air and 5% CO 2 at 37°C.…”

Section: Methodsmentioning

confidence: 99%

Cyclohexanone curcumin analogs inhibit the progression of castration‐resistant prostate cancer in vitro and in vivo

et al. 2018

Self Cite

View full text Add to dashboard Cite

Many prostate cancer patients develop resistance to treatment called castration‐resistant prostate cancer (CRPC) which is the major cause of recurrence and death. In the present study, four cyclohexanone curcumin analogs were synthesized. Additionally, their anticancer progression activity on CRPC cell lines, PC3 and PLS10 cells, was examined. We first determined their anti‐metastasis properties and found that 2,6‐bis‐(4‐hydroxy‐3‐methoxy‐benzylidene)‐cyclohexanone (2A) and 2,6‐bis‐(3,4‐dihydroxy‐benzylidene)‐cyclohexanone (2F) showed higher anti‐invasion properties against CRPC cells than curcumin. Analog 2A inhibited both MMP‐2 and MMP‐9 secretions and activities, whereas analog 2F reduced only MMP activities. These findings suggest that the compounds may inhibit CRPC cell metastasis by decreased extracellular matrix degradation. Analog 2A, the most potent analog, was then subjected to an in vivo study. Similar to curcumin, analog 2A was detectable in the serum of mice at 30 and 60 minutes after i.p. injections. Analog 2A and curcumin (30 mg/kg bodyweight) showed a similar ability to reduce tumor area in lungs of mice that were i.v. injected with PLS10 cells. Additionally, analog 2A showed superior growth inhibitory effect on PLS10 cells than that of curcumin both in vitro and in vivo. The compound inhibited PLS10 cells growth by induction of G1 phase arrest and apoptosis in vitro. Interestingly, analog 2A significantly decreased tumor growth with downregulation of cell proliferation and angiogenesis in PLS10‐bearing mice. Taken together, we could summarize that analog 2A showed promising activities in inhibiting CRPC progression both in vitro and in vivo.

show abstract

Section: Methodsmentioning

confidence: 99%

Cyclohexanone curcumin analogs inhibit the progression of castration‐resistant prostate cancer in vitro and in vivo

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…All animals were subjected to at least 2-weeks acclimatization period with the adaptation to a reverse 12 h light/dark cycle (dark phase set to 10:00 am–10:00 pm; visible light intensity <25 lux), and then used to model either regular physical exercise (i.e. forced wheel running model) or orthotopic PC development [PLS10 rat PC model ( Suzuki et al, 2015 )]—see Figure 1 for schematic overview. An individual animal served as an experimental unit in both models.…”

Section: Methodsmentioning

confidence: 99%

“…Rat prostate cancer cell line PLS10 was developed previously using chemically-induced prostate carcinoma in F344 rats ( Nakanishi et al, 1996 ; Suzuki et al, 2015 ). Cells were maintained in RPMI-1640 medium, supplemented with 10% FBS, 2 mM L-glutamine and 1x Antibiotic-Antimycotic at +37°C in a humidified atmosphere containing 5% CO2.…”

Section: Methodsmentioning

confidence: 99%

“…For modeling an orthotopic PC development, 21 F344 rats were used—the sample size of 7 animals per group (see Figure 1 for study groups) was calculated by statistical power analyses using G*Power software ( Buchner et al, 2021 ) and taking into account 80% power and α = 0.05, the published tumor size variation ( Suzuki et al, 2015 ), expected effect size and the chosen statistical test for the result analyses.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Exercise-Induced Extracellular Vesicles Delay the Progression of Prostate Cancer

Sadovska

Auders

Keiša

et al. 2022

Front. Mol. Biosci.

Self Cite

View full text Add to dashboard Cite

Increasing evidence suggests that regular physical exercise not only reduces the risk of cancer but also improves functional capacity, treatment efficacy and disease outcome in cancer patients. At least partially, these effects are mediated by the secretome of the tissues responding to exercise. The secreted molecules can be released in a carrier-free form or enclosed into extracellular vesicles (EVs). Several recent studies have shown that EVs are actively released into circulation during physical exercise. Here, we for the first time investigated the effects of exercise-induced EVs on the progression of cancer in an F344 rat model of metastatic prostate cancer. Although we did not observe a consistent increase in the circulating EV levels, RNA sequencing analysis demonstrated substantial changes in the RNA content of EVs collected before and immediately after forced wheel running exercise as well as differences between EVs from runners at resting state and sedentary rats. The major RNA biotype in EVs was mRNA, followed by miRNA and rRNA. Molecular functions of differentially expressed RNAs reflected various physiological processes including protein folding, metabolism and regulation of immune responses triggered by the exercise in the parental cells. Intravenous administration of exercise-induced EVs into F344 rats with orthotopically injected syngeneic prostate cancer cells PLS10, demonstrated reduction of the primary tumor volume by 35% and possibly—attenuation of lung metastases. Hence, our data provide the first evidence that exercise-induced EVs may modulate tumor physiology and delay the progression of cancer.

show abstract

“…Rat CRPC PLS10 cells were effectively established in our laboratory [31,32]. The cells were cultured in Roswell Park Memorial Institute-1640 medium (RPMI 1640, Gibco, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS, Thermo Scientific Company, Waltham, MA, USA) ), 5-mM L-glutamine, 50-IU/mL penicillin and 50-mg/mL streptomycin and maintained in a humidified incubator with an atmosphere comprised of 95% air and 5% CO 2 at 37 • C. When the cells reached 70-80% confluence, they were harvested and plated for subsequent passages or for Cur or DZG treatments.…”

Section: Cell Culturementioning

confidence: 99%

Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo

et al. 2020

Self Cite

View full text Add to dashboard Cite

Curcumin (Cur) exhibits biological activities that support its candidacy for cancer treatment. However, there are limitations to its pharmacological effects, such as poor solubility and bioavailability. Notably, the use of Cur analogs has potential for addressing these limitations. Dehydrozingerone (DZG) is a representative of the half-chemical structure of Cur, and many reports have indicated that it is anticancer in vitro. We, therefore, have hypothesized that DZG could inhibit prostate cancer progression both in vitro and in vivo. Results revealed that DZG decreased cell proliferation of rat castration-resistant prostate cancer, PLS10 cells, via induction of the cell cycle arrest in the G1 phase in vitro. In the PLS10 xenograft model, DZG significantly decreased the growth of subcutaneous tumors when compared to the control via the inhibition of cell proliferation and angiogenesis. To prove that DZG could improve the limitations of Cur, an in vivo pharmacokinetic was determined. DZG was detected in the serum at higher concentrations and remained up to 3 h after intraperitoneal injections, which was longer than Cur. DZG also showed superior in vivo tissue distribution than Cur. The results suggest that DZG could be a candidate of the Cur analog that can potentially exert anticancer capabilities in vivo and thereby improve its bioavailability.

show abstract

Establishment of a syngeneic orthotopic model of prostate cancer in immunocompetent rats

Cited by 4 publications

References 23 publications

Cyclohexanone curcumin analogs inhibit the progression of castration‐resistant prostate cancer in vitro and in vivo

Cyclohexanone curcumin analogs inhibit the progression of castration‐resistant prostate cancer in vitro and in vivo

Exercise-Induced Extracellular Vesicles Delay the Progression of Prostate Cancer

Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo

Contact Info

Product

Resources

About